---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-047166"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T22:55:20.123645+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma reports positive long-term Phase 1 Danon Disease data; PKD program enrollment delayed to 2025

## Summary
- All evaluable Danon disease patients showed cardiac LAMP2 protein expression at 12 months, sustained up to 60 months, and ≥10% LV mass index reduction sustained up to 54 months.
- Median reduction in LV mass index 24%; cardiac biomarkers cTnI down 84%, NTproBNP down 57%; NYHA class improved II to I; KCCQ score improved 27 points.
- RP-A501 generally well tolerated with manageable AEs; one patient with baseline LVEF<40% required heart transplant 5 months post-treatment.
- Phase 2 pivotal trial for Pyruvate Kinase Deficiency (RP-L301) design agreed with FDA; enrollment not started, anticipates resuming in 2025.

## SEC filing metadata
- accession: 0001140361-24-047166
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124047166/0001140361-24-047166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124047166/ef20038805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-047166
- JSON: https://secwatch.observer/filing/0001140361-24-047166.json
- Plain text: https://secwatch.observer/filing/0001140361-24-047166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.